# A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Study · id `cardio:ct-nct01095666` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01095666](<https://clinicaltrials.gov/study/NCT01095666>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01095666

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1484 participants.

## Technical summary

Registry record NCT01095666. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2017-09-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1484 participants (enrolled count; ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Results first posted: 2017-09-11 (ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Countries: China; India; South Korea (ClinicalTrials.gov record NCT01095666, source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01095666-2017-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Metformin
- Intervention (Drug): Dapagliflozin Placebo
- Intervention (Drug): Pioglitazone
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Astra Zeneca, Bristol-Myers Squibb
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Astra Zeneca, Bristol-Myers Squibb (`cardio:org-astra-zeneca-bristol-myers-squibb`)

## Provenance

Content hash: ab259c11c84f41a79e67221167cd0337f35f6d0d4da53064c432284dec6bcd92
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
